A serially coupled stationary phase method for the determination of urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine by liquid chromatography ion trap tandem mass spectrometry  by Rota, Cristina et al.
Research Paper
A serially coupled stationary phase method for the determination
of urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine by liquid
chromatography ion trap tandem mass spectrometry
Cristina Rota a,n, Simone Cristoni b, Tommaso Trenti a, Elisabetta Cariani a
a Laboratory of Toxicology, Department of Laboratory Medicine, Ospedale Civile S. Agostino Estense, Modena, Italy
b I.S.B. Ion Source & Biotechnologies Srl., Milan, Italy
a r t i c l e i n f o
Article history:
Received 27 September 2013
Accepted 8 October 2013
Keywords:
8-oxo-7,8-dihydro-2′-deoxyguanosine
LC-MS/MS
Ion trap
Urine
Reactive oxygen species
Oxidative stress
a b s t r a c t
Oxidative attack to DNA is of particular interest since DNA modiﬁcations can lead to heritable mutations.
The most studied product of DNA oxidation is 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG). While
8-oxodG determination in blood and tissue cells is prone to artifacts, its measurement in urine
employing liquid chromatography tandem mass spectrometry (LC-MS/MS) has gained more and more
interest for increased reliability. LC-MS/MS can be affected by matrix effects and this is particularly true
when ion trap is used as MS analyzer, due to ion accumulation in the trap and related space charge effect.
In the present work, we have developed a LC-MS/MS method where the combination of cation exchange
and reverse phase solid phases resulted in LC separation optimization. This together with the employ-
ment of an isotopically labeled internal standard, allowed the usage of ion trap LC-MS/MS, typically not
employed for quantitative measurement in biological samples, for the measurement of 8-oxodG in urine
samples from control populations.
Four different urine matrices were employed for method validation. Limit of quantitation was set at
least at 0.5 ng/ml. While analyzing urine samples from healthy volunteers, 8-oxodG levels reported as
ng/ml were statistically different comparing males with females (po0.05, Mann Whitney test); while
comparing results normalized for creatinine no statistical signiﬁcant difference was found. Mean urinary
8-oxodG level found in healthy volunteers was 1.1670.46 nmol/mmol creatinine.
The present method by enhancing at best the chromatographic performances allows the usage of ion
trap LC-MS/MS for the measurement of 8-oxodG in urine samples from control populations.
& 2013 The Authors. Published by Elsevier B.V.
Introduction
Normal cellular activity and exposure to oxidizing agents can
lead to the formation of reactive oxygen species (ROS). Oxidative
stress, the condition of oxidative imbalance implicated in many
human diseases, appears whenever ROS are produced in excess or
not adequately detoxiﬁed. ROS can attack biological macromole-
cules and the oxidative attack to DNA, in particular, is of interest
since DNA modiﬁcations can lead to heritable mutations. Due to its
low redox potential, guanine is one of the main targets of ROS in
DNA (and RNA). 8-Oxo-7,8-dihydroguanine is the most abun-
dant product of DNA oxidation, while 8-oxo-7,8-dihydro-2′-deox-
yguanosine is the most studied one, due both to the availability of
detection methods and its mutagenic potential [1,2]. The presence
of oxidative guanine derivatives in the DNA molecules, resulting in
base mispairing with adenine in place of cytosine, may be
mutagenic [3]. Determination of 8-oxodG in blood cells or tissues
is, in most cases, poorly reproducible and overestimated due to
artifactual oxidation during nucleic acid extraction and manipula-
tion [1,4]. It has to be reported, nevertheless, that recently the
Standard Committee on Oxidative DNA Damage (ESCODD net-
work) has published recommended protocols to keep at minimum
artifactual DNA oxidation [5,6], but still sample collection is not so
straightforward. During the last two decades the measurement of
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8-oxodG in urine has gained more and more interest, due to the non-
invasive method of sample collection, 8-oxodG long-term stability
in urine [7,8] and no artifactual DNA oxidation [9]. Another
important advantage of measuring 8-oxodG in urine resides in the
lack of sample manipulation, especially when employing LC-MS/MS
as detection technique. Recently, a series of recommendations
on urinary 8-oxodG determination, resulting from a large inter-
laboratory study have been published [10]. On the other hand, data
interpretation remains an incompletely resolved issue: urinary
levels of oxidized derivatives of nucleic acids, in fact, not only
depend on their formation upon oxidative attack, but also on
antioxidant defenses, on the extent of nucleic acid turnover and
on the efﬁciency of the repair systems, with Nudix hydrolase mut T
homologue 1 (MTH1) taking care of oxidized 2′-deoxyribonuleotide
repairing, while nucleotide excision (NER) and probably nucleotide
incision (NIR) repair systems, repairing the DNA molecule [11].
It has to be noted that the rationale behind the choice of
studying the oxidized nucleoside 8-oxodG and not the oxidized
base itself is related to the characteristic of the former of not being
inﬂuenced by the diet and so that urinary 8-oxodG is thought to
derive only from body's cells, although this is still an open issue [2].
LC-MS/MS is a powerful tool for the measurement of biomar-
kers in biological samples. Even if the powerfulness of this
analytical technique is universally recognized, it is also known
that LC-MS/MS can be affected by matrix effects, since biological
samples, like urine, are complex matrices containing many com-
pounds that can interfere with the target measurement [1,2,4,12].
This is particularly true for LC-MS/MS systems where ion trap is
used as MS analyzer, due to ion accumulation in the trap that lead
to space charge effect [13]. Time mass analyzers as ion traps,
chosen usually for the more affordable price compared to others,
do not perform as well if compared to spatial mass analyzers (e.g.
triple quadrupoles), when multiple reaction monitoring (MRM) is
performed [14,15].
In a previous work we developed a method where the
combination of surface-activated ionization (SACI) source with
electrospray ionization (ESI), together with cation-exchange chro-
matography, improving ion trap performances by the reduction of
matrix effects, enabled the measurement of 8-oxodG in diluted
urine [12]. In the present work, we went further in method
development and employed a different approach to liquid chro-
matography. Through the combination of cation exchange and
reverse phase solid phases we signiﬁcantly improved chromato-
graphic separation. This resulted in the possibility of increasing the
concentration of urine samples injected in the MS ion trap without
any further modiﬁcation. By this approach, together with the
employment of ESI ionization and the addition of an isotopically
labeled internal standard, we have signiﬁcantly improved the
analytical sensitivity, decreasing 6-fold the limit of quantitation
(LOQ) (from 3 ng/ml to at least 0.5 ng/ml).
Here are presented the results of method validation and the
data resulting from the measurement of 8-oxodG urinary levels in
a group of healthy volunteers.
Materials and methods
Reagents
8-oxodG, dimethyl sulfoxide (DMSO), formic acid, hydrogen
peroxide, ascorbic acid, ammonium hydroxide and potassium
phosphate monobasic (KH2PO4) were purchased from Sigma-
Aldrich (Milan, Italy). HPLC grade water and methanol were
purchased from Carlo Erba (Milan, Italy). Sep-Pak Vac 1 cc C18
SPE cartridges were purchased from Waters (Milford, MA, USA).
15[N5]2′-deoxyguanosine (15[N5]2-dG) was purchased from
Cambridge Isotope Laboratories (Andover, MA, USA). 15[N5]8-
oxodG was synthesized through the oxidation of 15[N5]2-dG accor-
ding to the method published by Hu et al. [16] upon minor
modiﬁcations as published by Andreoli et al. [1]. As reported in
the synthesis method, the yield of oxidized product is not ﬁxed
and can represent, at best, the 30% of the original 15[N5]2-dG. For
this reason a constant amount of internal standard was employed
in all experiments, but the reported concentration (25 ng/ml) is
purely theoretic. Aliquots of stock solutions of 8-oxodG (5 mM in
DMSO) and internal standard (IS) (theoretic 56.25 μM in 0.1 M
KH2PO4/methanol, 85/15 v/v) were stored at 80 and −20 1C,
respectively, until usage.
Chromatography
A serial stationary phase LC method was developed by con-
necting three LC columns as follows: ﬁrst a Biobasic SCX
502.1 mm, 5 μm, then an Aquasil C18 1502.1 mm, 5 μm and
ﬁnally an Aquasil C18 1002.1 mm, 3 μm. A Biobasic SCX
102.1 mm, 5 μm precolumn was also employed. All columns
were purchased from Thermo Scientiﬁc (Thermo Scientiﬁc, San
Jose, CA, USA). Chromatography was performed on an Ultimate
3000 HPLC (DIONEX, Germering, Germany). HPLC gradient was set
at a ﬂow rate of 150 μl/min using as eluents: (A) 0.5% (v/v) formic
acid/H2O and (B) 0.5% (v/v) formic acid in methanol. To prevent
contamination of the mass spectrometer, during the ﬁrst 15 min
and the last 25 min the eluate was diverted to the waste as it
contained a large amount of polar compounds derived from the
urine samples.
The columns were equilibrated for 3 min with 100% solution A,
then the percentage of eluent B was linearly incremented to 40% in
the following 17 min. Solution B percentage was further increased
to 80% from minute 20 to 22 and kept at 80% for 7.5 min. The
system returned to 100% of solution A in 30 s and columns were
re-equilibrated with it until the end of run (total run, 50 min).
Mass spectrometry
Mass spectra were acquired using a HCT Ultra ion trap spectro-
meter equipped with an electrospray ion source (Bruker Daltonics,
Bremen, Germany). Mass spectrometry was carried out by the
program Esquire Control (V6.2) and LC-MS was controlled by
Hystar (V3.2) (Bruker Daltonics, Bremen, Germany).
The spectrometer was operated in the positive mode with a
scan range from 100 to 400 m/z. MS parameter optimization was
obtained by directly infusing in the MS 14 μg/ml of 8-oxodG.
Optimized conditions were as follows: nebulizer pressure 25 psi,
dry gas 9 L/min, dry temperature 350 1C, capillary voltage of
4500 V with an end plate of 500 V.
MRM scans were performed by analyzing the following
ion transitions: transition of the precursor ion at 284 m/z to
the product ion at 168 m/z for 8-oxodG, and transition from the
parent ion at 289 m/z to the product ion at 173 m/z for the internal
standard (15[N5]8-oxodG). Ion isolation width was set to 2 m/z
with a fragmentation amplitude of 0.6 V.
Standards, internal quality controls (IQCs) and urine samples
were injected at least twice.
Standard, IQC and sample preparation
Working solutions (water) for 8-oxodG and internal standard
(IS) were prepared weekly. Further dilutions were made fresh
daily. Four different urine matrices were tested for the preparation
of standard curves and IQC. In particular, a stock solution contain-
ing urine matrix and IS was prepared upon usage, it was divided in
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equal amounts and adequate quantities of standard and/or water
were added to build up 8-point calibration curves (range 0–20 ng/
ml) and 2 level IQC (2.5, 5 ng/ml).
Urine samples derived from 49 healthy volunteers were col-
lected, thoroughly mixed and stored in aliquots at 80 1C. After
thawing and mixing, IS water solution was added to each urine
sample, centrifuged and injected in the LC-MS. Final dilution of
urine was 1:2 in samples, standards or IQC. The study was
approved by the Department of Laboratory Medicine review board
and all enrolled subjects gave written informed consent to
participate in the study.
Creatinine measurement
Quantitative measurement of urinary creatinine was performed
on an Architect ci8200 (Abbott Diagnostics Roma, Italy) by an
enzymatic method where creatinine is quantiﬁed through sarco-
sine/sarcosine oxidase reaction with the formation of a colored
compound characterized by an absorption maximum at 548 nm
[17].
Data analysis
MS data were processed by the employment of DataAnalysis
(V4.0 SP4) and concentrations calculated by QuantAnalysis (V2.0
SP4) (Bruker Daltonics, Breme, Germany). Excel (Microsoft, USA)
was employed for data elaboration and non-parametric statistic
calculations (Mann Whitney test) were performed by the employ-
ment of GraphPad Prism (V5.04) (GraphPad Software, Inc. La Jolla,
CA, USA).
Results
Method validation
Water solutions of 8-oxodG (10 ng/ml) and of 15[N5]8-oxodG IS
(theoretic concentration 25 ng/ml; see Materials and methods)
were employed to determine the retention time (rt) of both
compounds, that resulted 20.66 min70.04. and 20.67 min70.05
(mean of 10 replicates). By repeating the analysis of the same
solutions over a period of 5 months, we found a 1 min shift of the
rt. Further experiments were performed using human urine matrix
in order to obtain results closer to real biological samples, with
overlapping rt compared to water solutions. Fig. 1 shows the MS/
MS scan and the extracted ion chromatogram (EIC) of 2 ng/ml
8-oxodG added to urine matrix diluted to 1:2 in the presence of
15[N5]8-oxodG IS (theoretic concentration 25 ng/ml). The EIC and
the mass spectrum of 8-oxodG product ion (167.9 m/z), together
with the EIC and the mass spectrum of 15[N5]8-oxodG IS product
ion (172.9 m/z), are reported.
8-oxodG is an endogenous component of human urine. To
evaluate the inﬂuence of urine matrix on 8-oxodG determination,
four different urine samples were employed for the preparation of
standard curves by adding to each matrix increasing amounts of
8-oxodG standard (0, 0.5, 1, 2, 3, 4, 10 and 20 ng/ml) and a constant
amount of IS (estimated as 25 ng/ml). Standard curves derived
from matrix 1 did not include the 20 ng/ml point (Fig. 2). Each
matrix was employed to build up from four to seven distinct
standard curves, run in separate experiments. Results are reported
as 8-oxodG peak area/IS peak area. Good linearity and reproduci-
bility was reached thorough all the concentration range with all
matrices (R2 ranging from 0.9895 to 0.9992). Table 1 shows, in
detail, the comparison between mean target/IS area ratios for
matrix alone compared to matrix with the addition of 0.5 ng/ml
8-oxodG for all the 4 different matrices tested. Each data-point
was repeated at least 5 times in different analytical sets. Both the
CV% of matrix alone and of the 0.5 ng/ml 8-oxodG point was close
to 20% in most samples. However, in one case (matrix 3) about
8% CV% in the 0.5 ng/ml point was observed, together with lower
endogenous 8-oxodG/IS peak area ratio. Therefore 0.5 ng/ml was
deﬁned as the limit of quantiﬁcation of the method (LOQ), since
the CV% was largely o20% [18]. This result was also conﬁrmed by
the consecutive analysis of 15 replicates of a 0.5 ng/ml standard in
urine (data not shown). Matrix 3 was selected for the preparation
of standard curves employed for the analysis of urine samples
from healthy volunteers.
The same four urine matrices were employed for the produc-
tion of IQC samples. Two sets of IQCs were prepared by the
addition of 2.5 (level 1) or 5 ng/ml (level 2) of 8-oxodG in the
presence of IS. As reported in Table 2, recovery ranged from 86.8 to
103.6% for level 1 and from 98.8 to 115.4% for level 2, depending on
the urine matrix selected. Overall recovery (weighted mean of all
matrixes) was 96.8% for level 1 and 104.8% for level 2. The number
of between-day IQC repeats ranged from 5 to 11, with a total
amount of repeats of 25 for 2.5 ng/ml and 30 for 5 ng/ml 8-oxodG.
Overall CV% (weighted mean) was 14.79% for level 1 (range: 11.97–
16.98) and 11.61% for level 2 (range: 6.74–16.84). When consider-
ing matrix 3 (selected to be employed when dosing 8-oxodG in
healthy volunteers) recovery and CV% were 94.1% and 13.17% for
level 1 and 98.8% and 9.42% for level 2. After this initial evaluation,
IQCs were run in each analytical session.
Urine samples
Forty-nine healthy volunteers (25 females, 24 males) aged
21–65, mean 41.14711.89 years (females, 40.6711.82; males,
41.54712.21) were enrolled. Aliquots of urine samples from each
volunteer were frozen immediately at 80 1C and thawed just
before analysis. Before the injection in the LC-MS system, a
constant amount of internal standard was added to each sample,
that was injected at least two times during the analytical session.
In addition, most samples were measured in at least two different
analytical sessions. In Fig. 3 is represented the LC-MS/MS analysis
of a sample where 8-oxodG/IS peak area ratio was 0.74 and the
corresponding 8-oxodG concentration was 2.3 ng/ml (mean of
three analytical sessions). Considering that an 8-oxodG peak
area/IS peak area ratio of 0.3224 corresponds to 0.5 ng/ml
8-oxodG (the LOQ of the present method), all samples with
8-oxodG/IS peak area ratio o0.30 were considered as lower than
LOQ and were excluded from statistical analyses.
8-oxodG peak area/IS peak area ratios were differently dis-
tributed in males and females (Table 3), and signiﬁcantly higher
mean levels were detected in males compared to females
(po0.01). This difference was also observed when 8-oxodG levels
were expressed as ng/ml (po0.05). By contrast, when 8-oxodG
concentration was reported as μg/g creatinine, no statistically
signiﬁcant difference was found according to gender. As summar-
ized in Table 3 in fact, the different 8-oxodG levels found between
males and females were related to different urine concentrations,
as indicated by the detection of statistically higher creatinine
levels in males. The mean level of urinary 8-oxodG in the whole
population was 1.1670.46 nmol/mmol creatinine (weighted mean
7SD), 1.1270.4 in females and 1.1970.51 in males (Table 3).
The number of samples oLOQ was higher in females (6/25)
than in males (1/24): indeed, 8-oxodG area/IS area ratios o0.30
(oLOQ) were found only in samples with creatinine level o0.3 g/L.
8-OxodG was detectable in six out of these seven samples when
the analysis was repeated employing undiluted urine (data not
shown).
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Discussion
In the present paper we report the development of a LC-MS/MS
method based on the combination of different HPLC solid phases
(namely cation exchange and reverse phase) and a formic acid–
water/methanol gradient. This approach resulted in increased
efﬁciency of HPLC separation that allowed reliable quantitative
measurement of 8-oxodG in urine samples by the MRM technique,
employing an ion trap MS spectrometer. It is well known that the
ion trap detectors work best in full scan analysis than in MRM,
and that matrix effect, always an issue in LC/MS, is even more
problematic in ion traps due to ion accumulation combined with
space charge effect [13-15]. In a previously published work we
combined surface-activated ionization source with ESI, together
with cation-exchange chromatography, to improve ion trap per-
formances. This strategy enabled the reliable measure of 8-oxodG
in 1:10 diluted urine samples [12]. However, due to the low
amount of endogenous 8-oxodG in urine from healthy subjects,
this method was not sensitive enough to allow the detection of the
analyte in several cases (data not shown). Here enhanced liquid
chromatography performances resulted in the possibility of signiﬁ-
cantly decreasing sample dilution to a factor 1:2 and of using a
regular ESI ion source. We also improved method accuracy by
employing an isotopically labeled internal standard (chemically
oxidized 15[N5]8-oxodG). This approach, together with the normal-
ization of results by creatinine levels, is in line with the requirements
resulting from a large inter-laboratory study published recently [10].
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spectrum of 8-oxodG product ion (167.9 m/z). Panel C: EIC of 15[N5]8-oxodG product ion. rt 21.8 min., 172.970.2 m/z (289 m/z parent ion) smoothed (3.03 Gauss, 1 cycle).
Panel D: MS/MS mass spectrum of 15[N5]8-oxodG product ion (172.9 m/z).
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Fig. 2. Comparison of 8-oxodG standard in different urine matrixes (1:2 dilution).
Results reported as 8-oxodG peak area/IS peak area. Each matrix was employed
to build up from four to seven distinct standard curves. Data are shown as
mean7standard deviation (SD). Matrix 1 did not include the standard point at
20 ng/ml.
Table 1
Mean ratio 8-oxodG area/IS area in different urine matrices (1:2 dilution)70.5 ng/ml
8-oxodG.
Urine
matrix
Added 8-oxodG
(ng/ml)
8-oxodG area/IS area
(average)
SD CV% Repeats
1 0 0.4324 0.087 20.19 5
1 0.5 0.5667 0.125 22.04 5
2 0 0.3853 0.069 17.89 7
2 0.5 0.5121 0.086 16.78 6
3 0 0.2060 0.052 25.02 6
3 0.5 0.3224 0.027 8.36 5
4 0 0.3683 0.084 22.87 5
4 0.5 0.3976 0.082 20.70 5
CV%: between-day coefﬁcient of variation.
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To analyze the inﬂuence of the urine matrix on the detection of
8-oxodG, we compared the results obtained from 4 independent
urine samples spiked with increasing standard concentrations in
the range 0.5–20 ng/ml. Results were linear in all the range of
concentrations regardless of the matrix used. However, the LOQ
was strictly dependent on the matrix employed for the generation
of the calibration curve, and strongly inﬂuenced by its endogenous
8-oxodG content. Using a matrix with low endogenous 8-oxodG,
LOQ could be ﬁxed to at least 0.5 ng/ml (1.77 pmol/ml), a 6-fold
increased level of sensitivity compared to the SACI/ESI-based
method previously described [12]. The comparison with the
sensitivity of previously published LC/MS methods for 8-oxodG
Table 2
Two level internal quality controls prepared in different urine matrixes diluted 1:2. Accuracy and precision reported for each single matrix and for overall system.
ICQ level 1 (2.5 ng/ml)n 8-OxodG/IS (peak area)n ng/ml observed Recovery No. of repeats CV%
Matrix 1 0.9570.16 2.5970.31 103.6 5 11.97
Matrix 2 0.7570.12 2.1770.37 86.8 4 16.98
Matrix 3 0.7370.10 2.3570.31 94.1 6 13.17
Matrix 4 0.8070.10 2.4870.40 99.2 10 16.29
All matrixes 0.8070.11 2.4270.36 96.8 25 14.79
ICQ level 2 (5 ng/ml)n 8-OxodG/IS (peak area)n ng/ml observed Recovery No. of repeats CV%
Matrix 1 1.4270.34 5.7770.39 115.4 6 6.74
Matrix 2 1.2570.19 5.1470.48 102.8 7 9.44
Matrix 3 1.3270.17 4.9470.47 98.8 6 9.42
Matrix 4 1.3770.21 5.1870.87 103.6 11 16.84
All matrixes 1.3470.22 5.2470.60 104.8 30 11.61
n Data reported as mean7standard deviation.
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Table 3
Summary of results obtained in urine from healthy volunteers.
Gender 8-OxodG peak area/
IS peak area
8-OxodG
ng/ml
Creatinine
g/L
8-OxodG nmol/
mmol creatinine
Females
(n¼19)
0.59370.272 3.4072.33 0.9970.70 1.1270.40
Males
(n¼23)
0.78970.349 5.0772.98 1.6470.79 1.1970.51
po0.01 po0.05 po0.01 p¼0.39
Results reported as mean7SD. Samples with 8-oxodGoLOQ not included in
statistical calculations (Mann Whitney test).
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detection (all developed on triple quadrupole instruments) is
difﬁcult due to the different approaches used for LOQ determina-
tion. In some studies the chemically oxidized IS was employed
[1,19]. This approach avoids the problem of endogenous 8-oxodG,
but is ﬂawed by the uncertain concentration of IS due to the
variable efﬁciency of chemical oxidation necessary for the synth-
esis of the IS. In other studies, the method used for LOQ value
determination is not clearly explained [20,21]. Nevertheless,
reports describing 8-oxodG detection in urine by LC-MS/MS
[1,19–21] showed LOQ values in the range of 0.7–3.3 pmol/ml,
that are in line with the sensitivity of our method. It is also worth
noting that our results were obtained without any need for sample
processing and/or concentration, thus reducing the risk of artifac-
tual sample oxidation. The precision of the method was satisfac-
tory, with a CV% lower than 18% and less than 15% discrepancy
from expected values regardless of the matrix used for the
generation of the standard curve. These results are also compar-
able to those previously reported using triple quadrupole instru-
ments [1,19].
When we examined urine samples from healthy volunteers, we
observed a different distribution of 8-oxodG area/IS area ratios in
males and females, with signiﬁcantly higher mean ratios in males.
This difference was also observed when 8-oxodG levels were
considered in terms of concentration (ng/ml), but not when results
were normalized for creatinine urinary content. In fact, the main
difference found in males compared to females was related to
different urine concentrations, with statistically higher creatinine
levels in males. 8-OxodG area/IS area ratios o0.30, corresponding
to concentrations below LOQ, were found only in samples with
creatinine level o0.3 g/L, that were more frequent in females
(6/25) than in males (1/24), but 8-oxodG resulted detectable in
6 out of 7 samples when reanalyzed undiluted. A single study
found signiﬁcant higher 8-oxodG creatinine-normalized levels in
females compared to males [20], but other reports, including a
recent large inter-laboratory study, conﬁrmed that 8-oxodG levels
are not gender-related after correction for creatinine content
[10,19,21,22] underlining the need for creatinine correction for a
reliable assessment of 8-oxodG in urine [10].
In addition, mean urinary 8-oxodG level detected in the present
study (1.1670.46 nmol/mmol creatinine) is comparable with pre-
viously published data obtained by different LC-MS/MS methods
[1,10,19,21,22]. The consistency between our results and previous
reports obtained by the triple quadrupole MS/MS further supports
the reliability of the multi-stationary phase LC-ion trap MS
approach described in this report. Therefore the present method,
by enhancing at best the chromatographic performances, allows
the sensitive and accurate measurement of 8-oxodG in urine
samples by ion trap LC-MS/MS, typically not employed for quanti-
tative measurement in biological samples.
References
[1] R. Andreoli, P. Manini, G. De Palma, R. Alinovi, M. Goldoni, W.M.A. Niessen,
A. Mutti, Quantitative determination of urinary 8-oxo-7, 8-dihydro-2′-deox-
yguanosine, 8-oxo-7, 8-dihydroguanine, 8-oxo-7, 8-dihydroguanosine, and
their nonoxidized forms: daily concentration proﬁle in healthy volunteers,
Biomarkers 15 (2010) 221–231.
[2] H.E. Poulsen, L.L. Nadal, K. Broedbaek, P.E. Nielsen, A. Weimann, Detection and
interpretation of 8-oxodG and 8-oxoGua in urine, plasma and cerebrospinal
ﬂuid, Biochim. Biophys. Acta (2013). ([Epub ahead of print])http://dx.doi.org/
10.1016/j.bbagen.2013.06.009.
[3] S. Shibutani, M. Takeshita, A.P. Grollman, Insertion of speciﬁc bases during
DNA synthesis past the oxidation-damaged base 8-oxodG, Nature 349 (1991)
431–434.
[4] A.R. Collins, J. Cadet, L. Möller, H.E. Poulsen, J. Viña, Are we sure we know
how to measure 8-oxo-7,8-dihydroguanine in DNA from human cells? Arch.
Biochem. Biophys. 423 (2004) 57–65.
[5] C.M. Gedik, A. Collins, ESCODD, (European Standards Committee on Oxidative
DNA Damage). Establishing the background level of base oxidation in human
lymphocyte DNA: results of an interlaboratory validation study, FASEB J. 19
(2005) 82–84.
[6] J. Cadet, H. Poulsen, Measurement of oxidatively generated base damage in
cellular DNA and urine, Free Radicals Biol. Med. 48 (2010) 1457–1459.
[7] S. Loft, P. Svoboda, H. Kasai, A. Tjønneland, U. Vogel, P. Møller, K. Overvad,
O. Raaschou-Nielsen, Prospective study of 8-oxo-7,8-dihydro-2′-deoxyguano-
sine excretion and the risk of lung cancer, Carcinogenesis 27 (2006)
1245–1250.
[8] Y. Matsumoto, Y. Ogawa, R. Yoshida, A. Shimamori, H. Kasai, H. Ohta, The
stability of the oxidative stress marker, urinary 8-hydroxy-2′- deoxyguanosine
(8-OHdG), when stored at room temperature, J. Occup. Health 50 (2008)
366–372.
[9] H.S. Lin, A.M. Jenner, C.N. Ong, S.H. Huang, M. Whiteman, B. Halliwell, A high-
throughput and sensitive methodology for the quantiﬁcation of urinary
8-hydroxy-2′-deoxyguanosine: measurement with gas chromatography-
mass spectrometry after single solid-phase extraction, Biochem. J. 380
(2004) 541–548.
[10] L. Barregard, P. Møller, T. Henriksen, V. Mistry, G. Koppen, P. Rossner Jr,
R.J. Sram, A. Weimann, H.E. Poulsen, R. Nataf, R. Andreoli, P. Manini,
T. Marczylo, P. Lam, M.D. Evans, H. Kasai, K. Kawai, Y.S. Li, K. Sakai, R. Singh,
F. Teichert, P.B. Farmer, R. Rozalski, D. Gackowski, A. Siomek, G.T. Saez,
C. Cerda, K. Broberg, C. Lindh, M.B. Hossain, S. Haghdoost, C.W. Hu, M.
R. Chao, K.Y. Wu, H. Orhan, N. Senduran, R.J. Smith, R.M. Santella, Y. Su,
C. Cortez, S. Yeh, R. Olinski, S. Loft, M.S. Cooke, Human and methodological
sources of variability in the measurement of urinary 8-oxo-7;8-dihydro-2′-
deoxyguanosine, Antioxid. Redox Signal., 18, 2013; 2377–2391.
[11] M.D. Evans, M. Saparbaev, M.S. Cooke, DNA repair and the origins of urinary
oxidized 2′-deoxyribonucleosides, Mutagenesis 25 (2010) 433–442.
[12] S. Cristoni, L. Zingaro, C. Rota, E. Cariani, T. Trenti, A system consisting of
cation-exchange chromatography, combined surface-activated chemical and
electrospray ionization, and ion-trap analysis for the analysis of 8-oxo-7,8-
dihydro-2′-deoxyguanosine in urine, Rapid Commun. Mass Spectrom. 26
(2012) 231–235.
[13] S. Guan, A.G. Marshall, Equilibrium space charge distribution in a quadrupole
ion trap, J. Am. Soc. Mass Spectrom. 5 (1994) 64–71.
[14] W. Jan, W. Shou, R.W. Edom, N. Weng, M. Zhu, LC-MS in drug metabolism and
pharmacokinetics: a pharmaceutical industry perspective, in: M.S. Lee (Ed.),
Mass Spectrometry Handbook, John Wiley & Sons, 2012, pp. 119–170.
[15] E. Gangl, I. Utkin, N. Gerber, P. Vouros, Structural elucidation of metabolites
of ritonavir and indinavir by liquid chromatography-mass spectrometry,
J. Chromatogr. A. 974 (2002) 91–101.
[16] C.W. Hu, M.T. Wu, M.R. Chao, C.H. Pan, C.J. Wang, J.A. Swenberg, K.Y. Wu,
Comparison of analyses of urinary 8-hydroxy-2′-deoxyguanosine by isotope-
dilution liquid chromatography with electrospray tandem mass spectrometry
and by enzyme-linked immunosorbent assay, Rapid Commun. Mass Spectrom.
18 (2004) 505–510.
[17] E. Lamb, D.J. Newman, C.P. Price, Kidney function tests, in: C.A Burtis,
E.R. Ashwood, D.E. Bruns (Eds.), Tietz Textbook of Clinical Chemistry and
Molecular Diagnostics, Elsevier Saunders, St Louis, MO, 2006, pp. 797–835.
[18] Y.T. Chen, C.T. Parker, H.W. Chen, C.L. Chen, D. Domanski, D.S. Smith, C.C. Wu,
T. Chung, K.H. Liang, M.C. Chen, Y.S. Chang, C.H. Borchers, J.S. Yu, Assessment of
technical variation, LOD, LOQ in the MRM assay, in: P. Horvatovich, R. Bischoff
(Eds.), Comprehensive Biomarker Discovery and Validation for Clinical Appli-
cation. RCS Drug Discovery Series, 33, 2013, p. 298.
[19] P.M. Lam, V. Mistry, T.H. Marczylo, J.C. Konje, M.D. Evans, M.S. Cooke, Rapid
measurement of 8-oxo-7,8-dihydro-2′-deoxyguanosine in human biological
matrices using ultra-high-performance liquid chromatography-tandem mass
spectrometry, Free Radicals Biol. Med. 52 (2012) 2057–2063.
[20] A. Topic, D. Francuski, B. Markovic, M. Stankovic, S. Dobrivojevic, S. Drca,
D. Radojkovic, Gender-related reference intervals of urinary 8-oxo-7,8-dihy-
dro-2′-deoxyguanosine determined by liquid chromatography-tandem mass
spectrometry in Serbian population, Clin. Biochem. 46 (2013) 321–326.
[21] C. Mesaros, J.S. Arora, A. Wholer, A. Vachani, I.A. Blair, 8-Oxo-2′-deoxyguano-
sine as a biomarker of tobacco-smoking-induced oxidative stress, Free
Radicals Biol. Med. 53 (2012) 610–617.
[22] R. Andreoli, A. Mutti, M. Goldoni, P. Manini, P. Apostoli, G. De Palma, Reference
ranges of urinary biomarkers of oxidized guanine in (2′-deoxy)ribonucleotides
and nucleic acids, Free Radicals Biol. Med. 50 (2011) 254–261.
C. Rota et al. / Redox Biology 1 (2013) 492–497 497
